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Following rat heterotopic heart allotransplantation, 
low to lethal doses of the antimetabolites mizoribine 
(MIZ), RS-61443 (RS), and AZA were given alone or in 
combination with subtherapeutic doses of FK506 (0.04 
mg/kg/day) for 14 days after transplantation. With the 
median effect analysis of Chou and Kahan for quanti-
tative drug interactions, substantial therapeutic syn-
ergism was demonstrated between FK506 and non-
toxic doses of MIZ (2.5, 5, and 10 mg/kg/day) or AZA (5, 
30, and 45 mg/kg/day), which was particularly evident 
with the lowest dose MIZ (2.5 mg/kg/day). When FK506 
was used in combination with MIZ or AZA but not with 
RS, the maximum effect (peak median graft survival) 
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was enhanced significantly from 15 days (MIZ alone) 
to 26 days (P<O.05), and from 19 days (AZA alone) to 32 
days (P<O.OI). In contrast, RS interacted with FK506 
no more than additively. Although RS was the most 
powerful single antimetabolite, the best overall sur-
vival was obtained by combining AZA and FK506. The 
addition of FK506 did not significantly increase the 
percent mortality and LD50 of the antimetabolites. 
The strategy of multi pharmaceutical immunosuppressive 
therapy for organ transplantation is to enhance therapeutic 
efficacy while reducing the toxicity of individual drugs in the 
regimen. The dose-dependent side effects ofFK506, including 
nephrotoxicity, have prompted its clinical use with other 
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agents that have different sites of cellular and molecular 
action. The antimetabolite drugs RS-61443 (RS)* (1), mizo-
ribine (MIZ) (2), and AZA are candidates for combination 
with FK506 based on in vitro observations (3, 4). We report 
here companion in vivo studies with a heterotopic heart 
transplantation model, in which subtherapeutic doses of 
FK506 were combined with low to lethal doses of MIZ, AZA, 
or RS. Graft survival and lethal toxicity were the end points. 
Using the Chou median effect analysis (5, 6) advocated by 
Kahan (7, 8) to quantitate the combined drugs, MIZ andAZA 
at several different doses, but not RS 61443, were synergistic 
with low dose FK506. Lethal toxicity of the antimetabolite 
drugs was not changed significantly by their use with low 
dose FK506. 
MATERIALS AND METHODS 
Animals. Inbred male rats weighing 200-300 g were purchased 
from Harlan Spraque-Dawley Inc. (Indianapolis, IN). Lewis rats 
(LEW, RT1') and ACI rats (RT1 a) served as recipients and donors, 
respectively. Animals were maintained in conventional animal facili-
ties with water and commercial rat chow provided ad libitum. 
Heterotopic heart transplantation. The operation of Ono and 
Lindsay (9) was used with anastomosis of the donor to recipient 
aorta and the donor pulmonary artery to the recipient inferior 
vena cava. Graft pulsation, body weight, activity, and defecation 
patterns were monitored daily after transplantation. Rejection was 
established by cessation of heartbeat upon abdominal palpation 
and confirmed by direct inspection at laparotomy and histologic 
examination. 
Immunosuppression. All immun{)suppressive drugs were contin-
ued for 14 days, starting on the day of heart transplantation. FK506 
(a gift of the Fujisawa Pharmaceutical Co., Osaka, Japan) was sus-
pended in normal saline and given intramuscularly in daily doses of 
0.04 mg/kg. 'Ib this dose schedule, which was shown previously to be 
minimally immunosuppressive (10), the individual antimetabolite 
drugs were added. 
The antimetabolite drugs were prepared daily and administered 
alone or added to baseline FK506 by gastric instillation in the mini-
mal to lethal doses summarized in Tables 2, 3, and 4. RS (donated by 
Syntex Inc., Palo Alto, CAl was suspended in a special vehicle that 
contained 0.5% carboxymethylcellulose, 0.4% polysorbate 80, 0.9% 
benzyl alcohol, and 0.9% sodium chloride in distilled water. MIZ 
(Bredinin, donated by Asahi Chemical Industry Co. Ltd., 'Ibkyo, 
Japan) was dissolved in distilled water. AZA (lmuran, Burroughs 
Welcome Co., Research Triangle Park, NC) was bought from com-
mercial pharmacies and dissolved in distilled water. 
Statistical analysis. Graft survival (in days) was calculated from 
the date of allotransplantation until the date of graft failure or ani-
mal death. Grafts surviving more than 100 days were right censored. 
The Mann-Whitney U test (Wilcoxon rank sum test) was used for 
uncensored observations to assess the effect of combined therapy on 
graft survival compared with each drug treatment (excluding doses 
with >LDso). The maximum effect (peak median survival) of each 
antimetabolite alone or with FK506 was compared by using the 
Kruskall-Wallis test, a nonparametric test equivalent to the one-way 
analysis of variance, followed by the Mann-Whitney U test. Logistic 
regression was used to assess the effect ofFK506 on mortality and to 
estimate the LD5o. The results were considered significant if the 
P-value was < 0.05. 
The interaction between FK506 and antimetabolites was assessed 
using the median-effect analysis of Chou (5). The application of this 
method for in vitro and in vivo studies to quantify drug synergism or 
antagonism has been described previously (5--8). Synergism or an-
tagonism was expressed as the combination index (Cl), derived from 
* Abbreviations: CI, combination index; MIZ, mizoribine; RS, 
RS-61443. 
the equation (7, 8): 
CIx = (D} combined/D} alone) + (D z combined/D2 alone), 
where D} combined and D2 combined represent the amount of drug 1 
or 2, respectively, that is necessary in the combination to produce 
effect x. D} alone and D2 alone represent the amount of drug neces-
sary to produce the same effect x when used alone. CI values less 
than 1.0 suggest synergism, whereas those above 1.0 indicate an-
tagonism, and those equal to 1.0 indicate additivity. Only therapeutic 
doses of antimetabolites with <LD5o were used in the median-effect 
analyses. 
RESULTS 
Baseline FK506. As reported previously by Murase et al. 
(10) and confirmed with fresh controls, the median graft 
survival with baseline FK506 of 0.04 mg/kg/day was in-
creased from 6 to 9 days (Table 1). In the earlier studies, 
34-fold greater doses than this did not cause lethal toxicity, 
while therapeutic efficacy increased throughout (Fig. 1). 
Antimetabolite drug mono therapy. Median graft survival 
for each of the antimetabolite agents is given in Table 2 
(MIZ), Table 3 (AZA), and Table 4 (RS), and summarized from 
all experiments in Figure 2. With antimetabolite mono-
therapy, graft survival was prolonged with dose increments 
until this improvement was interrupted at higher doses by 
the mortality of overdosage. The peak median graft survival 
was 15 days for MIZ (at 15 mg/kg/day), 19 days for AZA (45 
mg/kg/day), and 23 days for RS (40 mg/kg/day). The differ-
ence was significant between RS and MIZ (P=0.04) but not 
between RS andAZA. Indefinite graft survival (>100 days) in 
2 experiments was achieved only with RS. 
Antimetabolites combined with FK506. All antimetabo-
lites when added to low dose FK506 provided better results at 
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TABLE 1. Graft survivals with FK506 treatment and 
untreated control 
FK506 (mg/kg) 
o 
0.04 
100 
90 
80 
70 
60 
50 
40 
30 
20 
10 
Graft survival days 
6,6,6,6,7,7,7 
7,7,7,8,8,9,9,10,12,12,37 
Median 
6 
9 
FK 506 (lIIg/kg/day) 
FIGURE 1. Relation of FK506 monotherapy dose (intramuscularly 
for 14 days) and graft survival (data for 0.08 to 1.28 mg/kg/day from 
Ref. 10). 
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TABLE 2. The effect of MIZ treatment with or without the addition of FK506 
MIZ FK506 Graft survival days" (mglkg/day) (mglkg/day) 
2.5 0 6,7,7,7,8 
5 0 8,8,9,11,11,13 
10 0 9,9,12,14,14,15 
15 0 11,14,15,15,16 
20 0 4*,12*,14*,20,21 
30 0 2*,5*,8*,11 *,13* 
2.5 0.04 12,12,16,21,24,27,28 
5 0.04 14,16,19,20,20,26 
10 0.04 13,17,26,28,29 
15 0.04 11 *,12*,21,21,21 
20 0.04 2*,4*,12*,9*,22 
30 0.04 4*,4*,4*,4*,5* 
Median' 
7 
9 
12 
15 
14 
8 
21 
19 
26 
21 
9 
4 
% Mortality 
0 
0 
0 
0 
60 
100 
0 
0 
0 
40 
80 
100 
LD50 (mg/kg/day) 
20 
16 
a Numbers with asterisk indicate that the rat died with a living graft. 
b Underlined numbers indicate the maximum median graft survival obtained using MIZ alone or in combination with FK506. 
TABLE 3. The effect of AZA treatment with or without the addition of FK506 
AZA FK506 Graft survival days" (mglkg/day) (mglkg/day) 
5 0 6,6,6,7,10 
30 0 7,8,11,12,17 
45 0 16,17,19,22,28 
60 0 10*,11 *,11 *,13*,13* 
90 0 5*,5*,11 *,21 
5 0.04 7,10,11,11,18,20 
30 0.04 26,27,28,29,29 
45 0.04 28,30,32,32,34 
60 0.04 12*,14 * ,30,32,32 
90 0.04 6* ,6* ,6* ,6* ,6* 
Medianb 
6 
11 
19 
11 
5 
11 
28 
32c 
30 
6 
% Mortality 
0 
0 
0 
100 
75 
0 
0 
0 
40 
100 
LD50 (mg/kg/day) 
53 
64 
a Numbers with asterisk indicate that the rat died with a living graft. 
b Underlined numbers indicate the maximum median graft survival obtained using AZA alone or in combination with FK506. 
C Maximum survival was significantly different from those of MIZ (P=0.02) or RS (P=0.04) treatment in combination with FK506. 
some doses (P<0.05) than when low dose FK506 was given 
alone. This was accomplished at doses of 2.5, 5.0, or 10.0 
mg/kg/day MIZ (Table 2), 30 or 45 mg/kg/day AZA (Table 3), 
and only 20 mg/kg/day RS (Table 4). MIZ at a dose of 2.5 
mg/kg/day had almost no effect on graft survival as a single 
agent, but markedly prolonged graft survival in combination 
with FK506. The maximum peak median graft survival was 
32 days using 45 mg/kg/day AZA in combination with FK506. 
This was longer than with the best monotherapy doses of 10 
mg/kg/day MIZ (P=0.03) and 40 mg/kg/day RS (P=0.43) (see 
also Fig. 2). 
Combination indices with antimetabolites and FK506. 
The CI for MIZ calculated from foregoing data (excluding 
doses with >LDso) were 0.64, 0.86, and 0.70 at doses of 2.5, 
5.0, and 10.0 mg/kg/day, indicating therapeutic synergism 
between MIZ and FK506 (Fig. 2a). Synergism was also seen 
(Fig. 2b) withAZAdoses of30 or 45 mg/kg/day (CI = 0.75 and 
0.80, respectively). However, a CI of 2.27 at the AZA dose of 
5 mg/kg/day suggested antagonism at this lower dose. The 
interaction between RS and FK506 was additive (CI = 1.00), 
but only at the RS dose of 20 mg/kg/day (Fig. 2c). The slight 
enhancement of the maximum effect observed at 40 mg/kg/ 
day was classified as "antagonism" (CI = 1.12). 
Toxicity of anti metabolites with and without FK506. The 
toxic dose with antimetabolite monotherapy was 2::20 mg/kg/ 
day for MIZ (Table 2) and 2::60 mg/kg/day for AZA (Table 3) or 
RS (Table 4). Percent mortality at each dose of antimetabolite 
was not affected significantly by combination with FK506. 
Animals with toxic doses of antimetabolites developed diar-
rhea and continuous weight loss, and some died with func-
tioning grafts. At the time of necropsy, severe edema of the 
intestinal mucosa was the most common finding. Lethal dose 
MIZ treatment frequently induced scattered hemorrhage and 
ulceration of the intestinal mucosa, which sometimes led to 
perforation. 
The LDso for each antimetabolite was calculated using lin-
ear logistic regression. These were 20 mg/kg/day for MIZ 
alone versus 16 mg/kg/day for MIZ+ FK506; 53 mg/kg/day for 
AZA alone versus 64 mg/kg/day for AZA + FK506; and 65 mg/ 
kg/day for RS alone versus 55 mg/kg/day for RS+ FK506. The 
minor increases or decreases of LDso doses with addition of 
FK506 to the individual metabolites (Tables 2-4) were not 
significant. 
DISCUSSION 
In analyzing our results, we accepted Berenbaum's (11) 
rigorous definition of "synergism" based on the dose-response 
relationship and have quantitated synergism by the median 
effect analysis of Chou (5) and Chou and Talalay (6), which 
has been advocated byVathsala et al. (7) and Kahan et al. (8) 
for in vivo as well as in vitro models. This method quantifies 
the interactions between 2 immunosuppressive agents at 
each dose combination as expressed by the CI. In our study, 
we calculated the CI at several dose combinations of the 
antimetabolite agents added to a fixed low dose ofFK506 and 
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TABLE 4. The effect of RS treatment with or without the addition of FK506 
RS FK506 Graft survival days a (mg/kg/day) (mg/kg/day) 
20 0 8,10,11,13,17,18,21 
40 0 13,18,23,25,26,30 
Medianb 
13 
23' 
% Mortality 
0 
0 
LD50 
(mg/kg/day) 
65 
60 0 5*,13* ,19,20,>100,>100 19 33 
80 0 3*,4*,4*,4* 4 100 
20 0.04 19,20,22,23,24,25 22 0 
40 0.04 24,25,27,31,34, 27 0 55 
60 0.04 12* ,13* ,13*,33,>100 13 60 
80 0.04 4*,4*,5*,5* 4 100 
a Numbers with asterisk indicate that the rat died with a living graft. 
b Underlined numbers indicate the maximum median graft survival obtained using RS alone or in combination with FK506. 
, Maximum survival was longer than that of MIZ monotherapy (P<0.05) and RS monotherapy (NS). 
a b C 
35 0.80 
0.75 ... 
30 0.70 1.16 
II> ... ;.., 
t'S 25 't:I 
r; 
~ 20 
'E 
::l 
'" 15 ~ 
t'S 
tb III 
c:: 
.!! 
't:I 5 
'" :,;
0 
0 10 20 30 II 20 40 60 80 100 0 20 40 60 80 
MIZ (lIIg/kg/dny) AZA (lIIg/kg/tiIlY) itS (lIIglkg/tlny) 
-0- wilhFK506 • without FK 506 . ........... _-- FK 506 alone 
FIGURE 2. Immunosuppressive effect on ACI-LEW heterotopic heart graft survival of various antimetabolite drugs given for 14 days alone 
(lower curves) or added to 0.04 mg/kg/day FK506 (upper curves). The combination index (CI numbers within the figure) was calculated from 
the graft survival achieved with each antimetabolite treatment at doses <LDso, and used to quantitate drug synergism between different 
doses of the antimetabolites and a fixed low dose ofFK506. *Survival significantly greater (P<0.05) than with antimetabolite monotherapy 
and fixed low dose FK506 monotherapy. 
also compared the maximum effect of each of these drugs 
when given alone. 
A benefit of combined immunosuppressive therapy for 
heart transplantation from ACI to LEW rats was clearly 
shown. Therapeutic synergism was present when FK506 was 
combined with either MIZ or AZA, whereas RS interacted 
with FK506 no more than additively. Therapeutic synergism 
was pronounced at the lowest dose of MIZ (2.5 mg/kg/day), 
but not with low dose AZA, which was antagonistic (5 mg/kg/ 
day). Low dose RS was not tested with FK506. Of the 3 
antimetabolites, RS gave the best graft survival when used 
alone, but the best results were obtained by combining AZA 
and FK506. 
A conventional explanation for drug synergism is the dif-
ferent site of action of the combined agents. Suppression of 
allospecific T cell immunity by FK506 is explained by inhi-
bition of the production ofIL-2 and its receptor (12). In con-
trast, MIZ, RS, and AZA inhibit purine biosynthesis, curtail-
ing the DNA synthesis necessary for cell division, including 
that of activated T and B lymphocytes (1, 2, 13). Thus, anti-
metabolites act at a late stage of the cell activation pathway 
by blocking the cell cycle between G1 to S (14), whereas 
FK506 acts at an early stage of T cell activation at the Go to 
G1 transition. Synergism resulting from these diverse anti-
lymphocytic mechanisms has been observed in in vitro test 
models, but less predictably so in vivo. In the whole animal, 
confounding factors that could cause divergence of in vitro 
from predicted in vivo results may include the alteration by 
each drug of the other agent's metabolism and elimination. In 
addition, an increasingly obfuscating recognized factor is a 
rapidly evolving change in host immune reactivity caused by 
ubiquitous engagement of migratory donor leukocytes that 
graft and mingle with immune cells of the recipient and 
survive for the life of the graft (15). Thus, the need for testing 
in whole animals versus reliance on surrogate in vitro models 
is evident. 
In addition to the desired effect of any drug combination, 
its utility depends on toxic interactions. In our experiments, 
the mortality of the recipients and the calculated LD50 did not 
change significantly by adding low dose FK506 to any of the 
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tested antimetabolites. Positive enhancement of the thera-
peutic effect without increasing toxicity indicates an im-
provement in therapeutic index (TI=LDso:EDso ratio) for 
these agents, with the promise of an increased clinical ben-
efit. However, clinically relevant side effects in the therapeu-
tic range could not be decisively assessed in this study. The 
rat model has little value for evaluating the adverse effects of 
FK506 in humans which have been broadly classified under 
nephrotoxicity, alteration in carbohydrate metabolism, neu-
rotoxicity, and susceptibility to infection and malignancy 
(16). 
The introduction of CsA and, more recently, FK506 has 
dramatically reduced the incidence and severity of acute cel-
lular rejection, but the risk of chronic rejection associated 
with proliferative arteriopathy remains high (17-20). Al-
though the pathogenesis of these vascular changes is dis-
puted, humoral antibodies are suspected to playa key role. 
Previous reports have suggested the utility of AZA and RS in 
reducing chronic vascular rejection (21,22). Because these 
drugs inhibit both T and B cell activity, combined immuno-
suppressive therapy that includes antimetabolites may offer 
a more effective means of preventing humoral as well as 
cellular rejection. Recently, the combination ofFK506 with a 
wide range of antimetabolites has been shown to mitigate the 
humoral rejection of hamster xenografts in rats to an extent 
far greater than with FK506 alone (23). 
In conclusion, we have demonstrated that after rat hetero-
topic heart allotransplantation there is therapeutic syner-
gism between MIZ or AZA, but not RS, and a fixed low dose 
ofFK506. The lethal toxicity ofthe antimetabolites alone was 
not affected by the addition ofthe FK506. The effect of higher 
dose FK506 in such combination therapy also remains to be 
elucidated. 
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